drugset / Trial / NCT03029741

Bioavailability of AZD0284 and IV Microtracer Study

NCT03029741 ↗

Phase 1 Completed 6 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. It occurs when skin cells are replaced more quickly than usual. The seriousness of psoriasis varies greatly from person to person. For some people it is a minor irritation, but for others it can have a major impact on their quality of life. . The purpose of the study is to determine how much of AZD0284 is taken up by the body. The safety and tolerability of the drug will also be assessed. It is hoped that the study drug will improve the management of psoriasis.

Timeline

Start
2017-02-21
Primary completion
2017-03-23
Completion
2017-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD0284 Unknown 20 ug Oral
Subject AZD0284 Unknown 4 mg Oral
Subject AZD0284 Unknown 120 mg Oral

Indications